Repligen (RGEN) to Release Earnings on Wednesday

Repligen (NASDAQ:RGEN) is expected to release its earnings data before the market opens on Wednesday, February 19th. Analysts expect Repligen to post earnings of $0.41 per share and revenue of $167.58 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Repligen Stock Up 0.5 %

Shares of RGEN stock opened at $146.92 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm’s 50-day moving average is $155.26 and its 200-day moving average is $148.82. The stock has a market cap of $8.23 billion, a price-to-earnings ratio of -397.07, a PEG ratio of 4.54 and a beta of 0.99. Repligen has a 52-week low of $113.50 and a 52-week high of $211.13.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several research analyst reports. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. HC Wainwright lowered their price target on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. TD Cowen initiated coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. Finally, Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $182.91.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.